Latest Patents

Patents imply intellectual property and it has a $ value that can be associated depending on the field and type of patent that is allocated. Patents also increase the enterprise value of the company and help prevent copy-cats from copying the idea without having royalt payments or licencing deals. We like it when companies get patents awarded!. To protect IP companies aggressively file provisional patents even before they have a working product. The below table provides a way to look at what has been done by companies and use this as a factor to make investment decisions.

     
Title Filing Date Publication Date Grant Date
Pyrrolobenzodiazepine phototherapy 2022-5-12 2022-6-29
Dosage regimes for the administration of an anti-cd19 adc 2022-3-18 2022-9-08
Site-specific antibody-drug conjugates 2022-3-01 2022-6-14
Combination therapy comprising an anti-cd19 antibody drug conjugate and a pi3k … 2021-12-06 2022-2-01
Combination therapy comprising an anti-cd25 antibody drug conjugate and a … 2021-12-06 2022-2-01
Pyrrolobenzodiazepine-antibody conjugates 2021-12-05 2022-2-01
Glycoconjugates 2021-10-14 2022-4-21
Combination therapy 2021-10-06 2022-4-14
Pyrrolobenzodiazepine-antibody conjugates 2021-9-24 2022-1-13
Pyrrolobenzodiazepine-antibody conjugates and uses thereof 2021-9-22 2022-3-31
Combination therapy comprising anti-kaag1 antibody drug conjugate and parp … 2021-8-05 2022-2-10
ANTI-IL13Rα2 ANTIBODIES 2021-7-30 2022-2-03
Combination therapy 2021-6-29 2021-8-11
Combination therapy 2021-6-29 2021-8-11
Combination therapy 2021-6-29 2021-8-11
Combination therapy 2021-5-28 2021-7-14
Combination therapy 2021-5-28 2021-7-14
Combination therapy 2021-5-28 2021-7-14
Pyrrolobenzodiazepine phototherapy 2021-5-13 2021-6-30
Pyrrolobenzodiazepine-antibody conjugates 2021-4-28 2021-8-26
Combination therapy 2021-2-23 2021-11-29
Molecular adjuvant 2021-2-19 2021-4-07
Combination therapy 2021-1-06 2021-9-20
Molecular adjuvant 2020-11-19 2021-6-28
Combination therapy 2020-11-06 2022-10-05
Compounds 2020-9-10 2020-10-28
Pyrrolobenzodiazepine-antibody conjugates 2020-8-19 2020-12-31
Pyrrolobenzodiazepine-anti-psma antibody conjugates 2020-8-06 2021-5-13
Pyrrolobenzodiazepine-antibody conjugates 2020-7-21 2020-11-05
Anti-mesothelin antibodies 2020-7-13 2020-8-26
Pyrrolobenzodiazepine-anti-cd22 antibody conjugates 2020-5-26 2020-10-01
Pyrrolobenzodiazepine phototherapy 2020-5-13 2020-6-24
Pyrrolobenzodiazepine-antibody conjugates 2020-3-02 2020-12-31
Antibodies against kidney associated antigen 1 and antigen-binding fragments … 2020-1-17 2020-5-21
Pyrrolobenzodiazepine resistance 2019-12-18 2021-10-27
Dosage regime 2019-11-25 2020-8-13
Compounds 2019-9-06 2019-10-23
Combination therapy 2019-6-10 2019-7-24
Combination Therapy 2019-6-10 2019-7-24
Combination therapy 2019-6-10 2019-7-24
Combination therapy 2019-6-10 2019-7-24
Combination therapy 2019-6-10 2019-7-24
Combination therapy 2019-6-10 2019-7-24
Agents for treating triple negative breast cancer 2019-5-22 2019-7-26
Pyrrolobenzodiazepine phototherapy 2019-5-17 2019-7-03
Pyrrolobenzodiazepine resistance 2019-3-28 2019-5-15
Treatment of car t-cell toxicity 2019-2-08 2022-6-09
Pyrrolobenzodiazepine resistance 2018-12-19 2019-1-30
Combination therapy with an anti-axl antibody-drug conjugate 2018-11-21 2019-7-18
Molecular adjuvant 2018-11-07 2018-12-19
PYROLOVENZODIAZEPINE-ANTIBODY CONJECTIONS AGAINST PSMA 2018-10-23 2019-12-11
Compounds 2018-9-05 2018-10-17
Combination Therapy 2018-8-31 2018-10-17
Molecular adjuvant 2018-8-10 2018-9-26
Pyrrolobenzodiazepine-antibody conjugates 2018-7-11 2018-8-29
Pyrroloobenzodiazepine-antibody conjugates 2018-7-11 2018-8-29
Dosage regimes for the administration of an anti-cd25 adc 2018-6-14 2018-12-20
Dosage Regime 2018-5-23 2018-7-11
Dosage regime 2018-5-23 2018-7-11
Combination therapy 2018-4-20 2020-2-26
Combination therapy with an anti-psma antibody-drug conjugate 2018-4-20 2018-10-25
Combination Therapy with Anti-CD25 Antibody-Drug Conjugates 2018-4-20 2019-12-11
Combination Therapy 2018-4-05 2018-5-23
Combination therapy 2018-3-29 2018-5-16
Dosage regime 2018-2-28 2018-4-11
Combination therapy 2018-2-23 2018-4-11
Dosage regime 2018-2-20 2018-4-04
Pyrrolobenzodiazepine-antibody conjugates 2018-2-08 2019-11-28
Pyrrolobenzodiazepines *-antibody conjugates 2018-2-08 2019-10-01
Pyrrolobenzodiazepine-antibody conjugates 2018-2-08 2022-3-17
Polynucleotides and polypeptide sequences involved in cancer 2018-1-05 2018-12-06
Dosage regime 2017-12-08 2018-1-24
Dosage regime 2017-12-08 2018-1-24
Dosage regime 2017-12-08 2018-1-24
Dosage regime 2017-12-08 2018-1-24
Antibodies that specifically block the biological activity of a tumor antigen 2017-12-06 2018-12-27
Pyrrolobenzodiazepine-antibody conjugates 2017-11-22 2018-1-03
Pyrrolobenzodiazepine-antibody conjugates 2017-11-22 2018-1-03
Pyrrolobenzodiazepine-antibody conjugates 2017-11-22 2018-1-03
Pyrrolobenzodiazepines Zhuo conjugate 2017-10-13 2019-6-04
PYRROLOVENZODIAZEPIN-ANTI-ANTIBODIES ANTIBODIES 2017-9-05 2018-2-14
Dosage regime 2017-6-30 2017-8-16
Dosage regime 2017-6-30 2017-8-16
Dosage regime 2017-6-30 2017-8-16
Dosage regime 2017-6-30 2017-8-16
Dosage regime 2017-6-14 2017-7-26
Dosage regime 2017-6-14 2017-7-26
Dosage regime 2017-6-14 2017-7-26
Dosage regime 2017-6-14 2017-7-26
For the antibody and application thereof of alpha-synapse nucleoprotein 2017-6-01 2019-3-15
pyrrolobenzodiazepine-peptide conjugates 2017-4-24 2017-6-07
Combination therapy 2017-4-20 2017-6-07
Combination therapy 2017-4-20 2017-6-07
Combination therapy 2017-4-20 2017-6-07
Combination therapy 2017-4-20 2017-6-07
Combination therapy 2017-4-20 2017-6-07
Combination therapy 2017-4-20 2017-6-07
Combination therapy 2017-4-20 2017-6-07
Combination therapy 2017-4-20 2017-6-07
Combination therapy 2017-4-20 2017-6-07